PGI2 as a regulator of inflammatory diseases

Stacy L Dorris, R Stokes Peebles Jr, Stacy L Dorris, R Stokes Peebles Jr

Abstract

Prostacyclin, or PGI(2), is an end product derived from the sequential metabolism of arachidonic acid via cyclooxygenase and PGI synthase (PGIS). The receptor for PGI(2), IP, can be found on a variety of cell types and signaling through this receptor exhibits broad physiological effects. Historically, PGI(2) has been understood to play a role in cardiovascular health, specifically having powerful vasodilatory effects via relaxation of smooth muscle and inhibiting of platelet aggregation. For these reasons, PGI(2) has a long history of use for the treatment of pulmonary arterial hypertension (PAH). Only recently, its importance as an immunomodulatory agent has been investigated. PGI(2) regulates both the innate and adaptive immune systems and its effects are, for the most part, thought to be anti-inflammatory or immunosuppressive in nature, which may have implications for its further clinical use.

Figures

Figure 1
Figure 1
PGI2 receptor signaling.

References

    1. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B. Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature. 1976;261(5561):558–560.
    1. Camacho M, Rodríguez C, Salazar J, et al. Retinoic acid induces PGI synthase expression in human endothelial cells. Journal of Lipid Research. 2008;49(8):1707–1714.
    1. Gurgul-Convey E, Lenzen S. Protection against cytokine toxicity through endoplasmic reticulum and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells. The Journal of Biological Chemistry. 2010;285(15):11121–11128.
    1. Jaffar Z, Wan KS, Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. Journal of Immunology. 2002;169(10):5997–6004.
    1. Camacho M, Rodríguez C, Guadall A, et al. Hypoxia upregulates PGI-synthase and increases PGI2 release in human vascular cells exposed to inflammatory stimuli. Journal of Lipid Research. 2011;52(4):720–731.
    1. Matsuoka T, Narumiya S. The roles of prostanoids in infection and sickness behaviors. Journal of Infection and Chemotherapy. 2008;14(4):270–278.
    1. Yin H, Cheng L, Langenbach R, Ju C. Prostaglandin I2 and E2 mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology. 2007;45(1):159–169.
    1. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306(5703):1954–1957.
    1. Hui Y, Ricciotti E, Crichton I, et al. Targeted deletions of cyclooxygenase-2 and atherogenesis in mice. Circulation. 2010;121(24):2654–2660.
    1. King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26(5):1137–1143.
    1. Zou MH, Ullrich V. Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. The FEBS Letters. 1996;382(1-2):101–104.
    1. Zou M, Martin C, Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biological Chemistry. 1997;378(7):707–713.
    1. Wade MI, Voelkel NF, Fitzpatrick FA. ‘Suicide’ inactivation of prostaglandin I2 synthase: characterization of mechanism-based inactivation with isolated enzyme and endothelial cells. Archives of Biochemistry and Biophysics. 1995;321(2):453–458.
    1. El-Haroun H, Clarke DL, Deacon K, et al. IL-1β, BK, and TGF-β1 attenuate PGI 2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. American Journal of Physiology. 2008;294(3):L553–L562.
    1. Mohite A, Chillar A, So SP, Cervantes V, Ruan KH. Novel mechanism of the vascular protector prostacyclin: regulating microRNA expression. Biochemistry. 2011;50(10):1691–1699.
    1. Soberman RJ, Christmas P. Revisiting prostacyclin: new directions in pulmonary fibrosis and inflammation. American Journal of Physiology. 2006;291(2):L142–L143.
    1. Lovgren AK, Jania LA, Hartney JM, et al. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. American Journal of Physiology. 2006;291(2):L144–L156.
    1. Dahlen SK, Hansson G, Hedqvist P, Bjorck T, Granstrom E, Dahlen B. Allergen challenge of lung tissue from asthmatic elicits bronchial contraction that correlates with the release of leukotrienes C4, D4, and E4. Proceedings of the National Academy of Sciences of the United States of America. 1983;80(6):1712–1716.
    1. Schulman ES, Newball HH, Demers LM, Fitzpatrick FA, Adkinson NF., Jr. Anaphylactic release of thromboxane A2, Prostaglandin D2, and prostacyclin from human lung parenchyma. American Review of Respiratory Disease. 1981;124(4):402–406.
    1. Takahashi Y, Tokuoka S, Masuda T, et al. Augmentation of allergic inflammation in prostanoid IP receptor deficient mice. British Journal of Pharmacology. 2002;137(3):315–322.
    1. Nagao K, Tanaka H, Komai M, Masuda T, Narumiya S, Nagai H. Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. American Journal of Respiratory Cell and Molecular Biology. 2003;29(3):314–320.
    1. Jaffar Z, Ferrini ME, Buford MC, FitzGerald GA, Roberts K. Prostaglandin I2-IP signaling blocks allergic pulmonary inflammation by preventing recruitment of CD4+ Th2 cells into the airways in a mouse model of asthma. Journal of Immunology. 2007;179(9):6193–6203.
    1. Wang M, Cooper PR, Jiang M, et al. Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness. Journal of Pharmacology and Experimental Therapeutics. 2010;334(1):63–68.
    1. Idzko M, Hammad H, van Nimwegen M, et al. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. Journal of Clinical Investigation. 2007;117(2):464–472.
    1. Madison LD, Scarlett JM, Levasseur P, et al. Prostacyclin signaling regulates circulating ghrelin during acute inflammation. Journal of Endocrinology. 2008;196(2):263–273.
    1. Vane J, Corin RE. Prostacyclin: a vascular mediator. European Journal of Vascular and Endovascular Surgery. 2003;26(6):571–578.
    1. Lehmann C, König JP, Dettmann J, Birnbaum J, Kox WJ. Effects of iloprost, a stable prostacyclin analog, on intestinal leukocyte adherence and microvascular blood flow in rat experimental endotoxemia. Critical Care Medicine. 2001;29(7):1412–1416.
    1. Nana-Sinkam SP, Jong DL, Sotto-Santiago S, et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. American Journal of Respiratory and Critical Care Medicine. 2007;175(7):676–685.
    1. Zhu Y, Liu Y, Zhou W, et al. A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respiratory Research. 2010;11, article 34
    1. Zhou W, Dowell DR, Geraci MW, et al. PGI synthase overexpression protects against bleomycin-induced mortality and is associated with increased Nqo 1 expression. American Journal of Physiology. 2011;301(4):L615–L622.
    1. Hashimoto K, Graham BS, Geraci MW, et al. Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness. Journal of Virology. 2004;78(19):10303–10309.
    1. Hashimoto K, Ishibashi K, Gebretsadik T, et al. Functional polymorphism of the promoter region of the prostacyclin synthase gene and severity of RSV infection in hospitalized children. Journal of Medical Virology. 2008;80(11):2015–2022.
    1. Pulichino AM, Rowland S, Wu T, et al. Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. Journal of Pharmacology and Experimental Therapeutics. 2006;319(3):1043–1050.
    1. Honda T, Segi-Nishida E, Miyachi Y, Narumiya S. Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. Journal of Experimental Medicine. 2006;203(2):325–335.
    1. Aronoff DM, Peres CM, Serezani CH, et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. Journal of Immunology. 2007;178(3):1628–1634.
    1. Hung CH, Chu YT, Suen JL, et al. Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues. European Respiratory Journal. 2009;33(2):405–410.
    1. Konya V, Sturm EM, Schratl P, et al. Endothelium-derived prostaglandin I2 controls the migration of eosinophils. Journal of Allergy and Clinical Immunology. 2010;125(5):1105–1113.
    1. Lee IY, Ko EM, Kim SH, Jeoung DI, Choe J. Human follicular dendritic cells express prostacyclin synthase: a novel mechanism to control T cell numbers in the germinal center. Journal of Immunology. 2005;175(3):1658–1664.
    1. Müller T, Dürk T, Blumenthal B, et al. Iloprost has potent anti-inflammatory properties on human monocyte-derived dendritic cells. Clinical and Experimental Allergy. 2010;40(8):1214–1221.
    1. Strassheim D, Riddle SR, Burke DL, Geraci MW, Stenmark KR. Prostacyclin inhibits IFN-γ-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner. Journal of Immunology. 2009;183(11):6981–6988.
    1. Zhou W, Blackwell TS, Goleniewska K, et al. Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells. Journal of Leukocyte Biology. 2007;81(3):809–817.
    1. Zhou W, Hashimoto K, Goleniewska K, et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. Journal of Immunology. 2007;178(2):702–710.
    1. Kuo CH, Ko YC, Yang SN, et al. Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation. Journal of Molecular Medicine. 2011;89(1):29–41.
    1. Nakajima S, Honda T, Sakata D, et al. Prostaglandin I2-IP signaling promotes Th1 differentiation in a mouse model of contact hypersensitivity. Journal of Immunology. 2010;184(10):5595–5603.
    1. Kim J, Park CS, Park CH, Jeoung DI, Kim YM, Choe J. Beraprost enhances the APC function of B cells by upregulating CD86 expression levels. Journal of Immunology. 2011;186(7):3866–3873.
    1. Ivy DD. Prostacyclin in the intensive care setting. Pediatric Critical Care Medicine. 2010;11(2):S41–S45.
    1. Murakami S, Nagaya N, Itoh T, et al. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. American Journal of Physiology. 2006;290(1):L59–L65.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi